The reductions in all three CSF Aβ peptides are independent of co-morbid AD pathology or APOE genotype, suggesting that Aβ metabolism is affected in DLB, even in the absence of co-morbid AD pathology, and that different pathogenic biological processes may be involved in Aβ-peptide-related amyloidogenesis in DLB versus AD [11]. The gene discussed is APOE; the disease is Lewy body dementia.